Drug Trial Radar · NCT03730142
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Oct 25, 2018
Primary completion
Jul 25, 2020
Study completion Jul 25, 2020
Sponsor
- Lead sponsor
- Shanghai Jiatan Pharmatech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
WXFL10030390 (WX390) is a novel oral small molecular that inhibits phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) and has demonstrated potent inhibitory effects on multiple human tumor xenografts. The first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of WX390 at single dose and multiple doses.
Conditions
- Advanced Cancer
Interventions
WXFL10030390Drug
WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0Time frame: From first dose to within 30 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.